|
Featured stock: ScripsAmerica, Inc. (SCRC)
This Company's Technology
Just Reinvented the
Toddler's Medicine Market.
This Breakthrough Children's Medicine Is in the final stages of approval
in Hong Kong. China, And Its 300 Million Children Await.
ScripsAmerica Inc (SCRC) is one of the hottest penny stocks of 2015. Three months ago, SCRC shares were trading at 11¢. The stock closed yesterday a whopping 61% higher at 18¢. That's an astounding 61% return in just over 3 months!
Even after this 61% move, investors are still buzzing about some recent developments which I'll outline in a minute. While SCRC is usually a pretty quiet stock, it's capable of explosive moves.
Take a look at the move in July 2013 when the stock traded up to 97¢:
And this 97¢ high was almost in a straight line from 14¢. That's a 692% return in a matter of days!
Now you're probably thinking to yourself, "What the heck is this product that's going to reinvent the children's Tylenol market?"
Allow me to explain. Anyone with sick kids knows how difficult it can be to get them to take fever reducer and pain reliever meds. Kids are difficult, and they're borderline impossible when they're sick. We all know medicine tastes terrible, especially for a child who is unable to swallow an entire pill or capsule. Let's face it, Mary Poppins' "spoonful of sugar" recommendation was never an adequate solution.
Drug behemoth Tylenol's "Children's TYLENOL® Meltaways® Chewable Tablets" was recalled in 2010 because the medicine left a "terrible odor" in children's mouths. Since then, Tylenol hasn't put a new product on the shelves. It appears that Rapimed is ready to fill this void.
http://www.rapimeds.com/index.php
RapiMed® Pain Reliever & Fever Reducer delivers accurate dosage in three simple steps:
- Put the tablet on your child's tongue.
- Allow the tablet to dissolve in your child's mouth.
- The tablet melts away in your child's mouth.
No more need for measuring cups, spoons, or water!
And it's Gluten Free. Sugar Free. Aspirin Free. Ibuprofen Free.
Rapimed's two flavors - Bubblegum and Wild Grape- are available for children age 2-6 or 6-11 years old.
So why SCRC now?
Well, Rapimed was recently granted approval for distribution in Hong Kong, and this is a big deal. On an investor conference call last week, CEO Robert Schneiderman said the first shipment of $200,000 worth of Rapimed "will happen in the next 2 to 3 weeks."
(You can read the transcript of the call here.)
Now, in comparison to the billions of $'s in revenues by companies like Pfizer (PFE) and Merck (MRK), $200,000 is miniscule. However, keep in mind that this is just the tip of the iceberg for SCRC, a microcap company with a market cap of $25mm that's poised for tremendous growth in the coming months.
To put this in perspective, the Chinese marketplace is 5 times the size of the US. If SCRC's Rapimed simply carves out a small slice of the Chinese pediatric medicinal market, the stock could command a market cap significantly larger than the current one of $25mm.
Key developments include:
- At the end of last year, the company secured a $4 million line of credit from Triumph Healthcare Finance. This line of credit will be used by ScripsAmerica to fund the expansion of its specialty pharmacy operations in the US and pay off its current high interest debt.
- ScripsAmerica was profitable during the 3rd quarter of 2014, with growing profit margins in its compounding business and plans to eliminate any further dilution of its stock for financing purposes moving forward.
- In December, 2014, the company acquired a 90% interest in the Florida-based pharmaceutical wholesale company PIMD International, a wholesaler to pharmacies, hospitals, and physician's offices in the US. PIMD International, LLC, ("PIMD"), reported revenue of $137,031 during the month of January 2015, the highest monthly revenue in the company's history.
- In January, ScripsAmerica, through it's Main Avenue Pharmacy, launched a diabetes patient supply program.
- This initiative provides diabetes patients in certain states with medical supplies that are only available through a physician's prescription and typically covered by medical insurance and Medicare.
- In addition, the company also created a marketing subdivision focused on Spanish speaking diabetics, a market segment they believe is not only growing quickly but is also largely underserved.
- Just last week, the company announced 500 new subscribers to the patient supply program- in just the first month.
And that's why SCRC is our Blazing Stock of the Week!
ScripsAmerica, Inc. (OTCBB: SCRC) is a supplier of prescription, OTC and nutraceutical drugs, responsible for delivering pharmaceutical products to a wide range of end users across the healthcare industry. End users include retail pharmacies, hospitals, long-term care facilities and government and home care agencies. For more information, visit www.ScripsAmerica.com.
Tylenol recall article: http://money.cnn.com/2010/01/15/news/companies/over_the_counter_medicine_recall/
|
